NCT01436045View on ClinicalTrials.gov

Safety and Effectiveness Study of Intranasal Insulin Glulisine on Cognitive and Memory in Mild-Mod AD Patients.

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Alzheimer's Disease
Interventions
DRUG

Insulin glulisine

Single treatment, 20 IU/Intranasal (.1ml/10 units Intranasally in each nostril)

DRUG

Saline

Single treatment,(saline) 20 IU/Intranasal (.1ml/10units intranasally in each nostril)

Trial Locations (1)

55130

HealthPartners Specialty Center - Center for Dementia & Alzheimer's Care, Saint Paul

All Listed Sponsors
lead

HealthPartners Institute

OTHER

NCT01436045 - Safety and Effectiveness Study of Intranasal Insulin Glulisine on Cognitive and Memory in Mild-Mod AD Patients. | Biotech Hunter | Biotech Hunter